Nicholas C. Turner, Kevin Kalinsky, Katherine E. Hutchinson, Yanling Jin, Tiffany D. Clark, Komal L. Jhaveri, Sibylle Loibl, Cristina Saura Manich, Christine Desmedt, Hans Wildiers, Seock-Ah Im, Patrick Neven, Peter Schmid, Dejan Juric, Sherene Loi, Stephanie Hilz, Thomas J. Stout. "Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with PIK3CA -mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.1079